PMPrasenjit Maity

Prasenjit Maity

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Prasenjit Maity has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Six‐Membered N ‐Heterocycle Antidiabetic Agents: Structure–Activity Relationships and Molecular Insights

    by Rajarshi Nath, Lakshminarayan Das, Arka Chakraborty, Anhic Chakraborty, Shah Alam Khan, Soumyadeep Bakshi, Sk Masud Hassan, Nasim Sk, Tribeni Karak, Prasenjit Maity, et al.

    Over the past several decades, extensive research has led to the development of inhibitors targeting α‐glucosidase, α‐amylase, and peroxisome proliferator–activated receptors (PPARγ) for the management of diabetes. However, the currently available antidiabetic drugs suffer from the limitations of toxicity and resistance, highlighting the need for safer and effective therapeutic agents. Six‐membered nitrogen‐containing heterocycles, their structural versatility and pharmacophoric features, exhibit diverse biological activities. The nitrogen atoms present in heterocyclic rings enhance the hydrogen‐bond interactions with key diabetes‐associated targets, thereby improving receptor binding and pharmacological performance. Recently published studies have increasingly focused on molecular hybridization strategies that incorporate nitrogen‐containing heterocycles into the core structures to yield new hybrid molecules that enhance insulin sensitivity while optimizing their efficacy and safety profiles. This review summarizes recent advances in synthetic methodologies, molecular modelling, and structure–activity relationship (SAR) analyses of nitrogen‐containing six‐membered heterocycles over the past 5 years (2020–25) targeting diabetes. The heterocyclic scaffolds discussed include the core six‐membered N ‐heterocycles such as triazine, pyridine, pyrimidine, piperidine, piperazine, and morpholine, along with their structurally diverse derivatives. Moreover, insights gained from these investigations provide a rational framework for the design and development of next‐generation antidiabetic agents with enhanced selectivity, reduced toxicity, and improved pharmacological profiles.

  • A Comprehensive Review of Phosphodiesterases 4 (PDE4) Inhibitors in Clinical Trials

    by Raghu Prasad Mailavaram, Yogesh Chaudhari, Ritesh S. Tarwani, Katharigatta N. Venugopala, Manik Ghosh, Prasenjit Maity, Pran Kishore Deb

    Phosphodiesterase 4 (PDE4) facilitates the enzymatic breakdown of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), through its four distinct isotypes, namely PDE4A to PDE4D, along with more than 25 splice variants. It plays a crucial role in cancer development, respiratory issues such as asthma and chronic obstructive pulmonary disease (COPD), autoimmune diseases like psoriasis, and neurological disorders such as Alzheimer’s disease. Various methods are being developed to enhance clinical efficacy and reduce side effects. Some of these methods include drug delivery via inhalation and the development of non-emetic PDE4 inhibitors and mixed PDE inhibitors. These inhibitors offer several advantages over traditional formulations, including selectivity for specific inhibitors, targeted tissue distribution, and oral effectiveness. All these efforts have led to the emergence of novel PDE4 inhibitors, with some having progressed to clinical trial stages and others approved as medications. This review summarises PDE4 inhibitors currently in clinical trials, highlighting their therapeutic potential, limitations, and future prospects.


  • Computational Repurposing of Roxadustat Targeting HIF-1α and EGFR in Acute Lung Injury and Ischemic Hypoxia

    by Vivek Bakshi, Amrita Chatterjee, Prasenjit Maity, Ankit Chowdhury, Tanishk Saini, Shreyashi Pal, Adib Alam, Monami Bhattacharyya, Biswatrish Sarkar, Pran Kishore Deb, et al.

    Acute lung injury (ALI) and ischemic hypoxia (IH) remain significant clinical challenges due to their pathophysiologically linked conditions characterized by uncontrolled inflammation, alveolar damage and severe oxygen deprivation. Despite the high disease burden, therapeutic options remain extremely limited, with Pentoxifylline (PTX) being one of the few available pharmacological agents offering only moderate efficacy; however, its limited therapeutic reach and adverse effects highlight a critical gap in the current pharmacological landscape and underscore the necessity for innovative, mechanism-driven therapeutic alternatives. This study investigates a novel repurposing strategy by evaluating the potential of Roxadustat (RXT), a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), initially approved for anemia in chronic kidney disease, in comparison with PTX, using an in silico multi-omics approach. We employed data mining from DrugBank, GeneCards and SwissADME to identify intersecting targets of both drugs with ALI and IH. Protein-protein interaction (PPI) networks, KEGG pathway enrichment and hub gene analyses revealed a distinct mechanistic advantage of RXT, revealing its significant engagement with key signaling pathways, especially EGFR and HIF-1[ ], as opposed to PTX. This mechanistic novelty is further validated through molecular docking, which confirmed higher binding affinities of RXT with EGFR and HIF-1[ ], indicating its stronger interactions than PTX. Molecular dynamics simulations over 100 ns further confirmed the greater stability and persistent residue-specific interactions of RXT-EGFR and RXT-HIF-1[ ] complexes through RMSD, RMSF, and protein–ligand contact analyses. RXT consistently exhibited stronger and more stable interactions with critical residues, indicating greater pharmacodynamic potential. These findings are reinforced by the KEGG analysis, which highlights engagement of RXT with the HIF-1[ ] signaling pathway, which is absent in PTX. Overall, the study results demonstrate RXT as a mechanistically relevant and pharmacodynamically strong candidate for drug repurposing with a superior prospect for managing ALI and IH. This study lays the groundwork for future preclinical validation and encourages translational exploration of RXT in hypoxia-related pulmonary conditions and disorders.

  • Recent Trends in the Development and Clinical Translation of Polymer-based Targeted Therapeutic Nanoparticle

    by Chandan Kumar Singh, Ratnali Bania, Satyendra Deka, Monika Dwivedi, Anroop B. Nair, Trishna Bal, Prasenjit Maity, Pran Kishore Deb

    Polymeric nanoparticles are a state-of-the-art innovation in nanomedicine, offering site-specific drug delivery, an improved pharmacokinetic profile, and a


  • Open Access

    Therapeutic potential of adenosine receptor modulators in cancer treatment

    by Prasenjit Maity, Swastika Ganguly, Pran Kishore Deb

    All human cells contain the universal autocoid adenosine, which interacts with four types of G protein-coupled receptors (GPCRs), namely A1, A2A, A2B, and A3 adenosine receptors (ARs). Among these receptors, A2A and A2B ARs activate adenylate cyclase, while A1 and A3 ARs suppress the adenylate cyclase activity. Adenosine-receptor interactions play a crucial role in cancer biology by modulating the immune microenvironment, which tumors exploit to create immunosuppression that promotes their growth and metastasis. When the A2A AR is activated on natural killer (NK) cells and T cells, it reduces their ability to carry out cytotoxic functions. This activation also encourages the formation of immune-suppressing cell types, such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), further weakening the immune response. Targeting adenosine receptors, particularly the A2A subtype, represents a promising therapeutic strategy. By antagonizing these receptors, it may be possible to restore T cell function, helping the body to recognize and attack cancer cells more effectively. Despite recent advancements in the discovery of novel, targeted anticancer agents, these treatments have shown limited effectiveness against metastatic tumours, complicating cancer management. Moreover, developing adenosine receptor agonists or antagonists with high target selectivity and potency remains a significant challenge, as the widespread distribution of adenosine receptors throughout the body raises concerns about off-target effects and reduced therapeutic efficacy. In order to improve outcomes for patients with advanced cancer, researchers are actively investigating safer and more efficient chemotherapy substitutes. However, drugs that activate A3 adenosine receptors and block A2A receptors are being explored as a novel approach for cancer treatment. Monoclonal antibodies and small-molecule inhibitors targeting the CD39/CD73/A2A AR axis are also being tested in clinical trials, both as standalone treatments and in combination with anti-PD-1/PD-L1 immunotherapies. This review primarily focuses on the signaling pathways and the therapeutic potential of various adenosine receptor agonists and antagonists across various cancer types, highlighting their ongoing evaluation in preclinical and clinical trials, both as monotherapies and in rational combination with immunotherapy, chemotherapy, or targeted therapies, potentially leading to the development of advanced treatments that could aid in tumor suppression.